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ABSTRACT
Background: Deletion of chromosome 5q (del(5q)) is the most common 
karyotypic abnormality in myeloid neoplasms.
Materials and Methods: To define the pathogenic molecular features associated 
with del(5q), next–generation sequencing was applied to 133 patients with myeloid 
neoplasms (MDS; N = 69, MDS/MPN; N = 5, sAML; N = 29, pAML; N = 30) with del(5q) 
as a sole abnormally or a part of complex karyotype and results were compared to 
molecular features of patients diploid for chr5.
Findings: A number of 5q genes with haploinsufficient expression and/or 
recurrent somatic mutations were identified; for these genes, CSNK1A1 and G3BP1 
within the commonly deleted 5q region and DDX41 within a commonly retained region 
were most commonly affected by somatic mutations. These genes showed consistent 
haploinsufficiency in deleted cases; low expression/mutations of G3BP1 or DDX41 
were associated with poor survival, likely due to decreased cellular function. The most 
common mutations on other chromosomes in patients with del(5q) included TP53, and 
mutations of FLT3 (ITD or TKD), NPM1 or TET2 and were mutually exclusive. Serial 
sequencing allowed for definition of clonal architecture and dynamics, in patients with 
exome sequencing allelic imbalance for informative SNPs facilitated simultaneous 
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INTRODUCTION
Interstitial deletion of the long arm of chromosome 
5 (del(5q)), is the most common karyotypic abnormality in 
myeloid neoplasms, observed in 10–15% of patients with 
myelodysplastic syndromes (MDS) [1–5] or primary acute 
myeloid leukemia (pAML) [6, 7], and in up to 40% of 
secondary myeloid leukemias (sAML) [8]. While a smaller 
fraction of more homogenous patients with the isolated 
del(5q) and classical 5q- syndrome show more favorable 
prognosis [9, 10], the majority of myeloid neoplasms with 
del(5q) are morphologically heterogeneous, and have 
additional cytogenetic abnormalities [7, 11, 12].
The commonly deleted regions (CDR) in del(5q) 
have been extensively studied with a distal region 
(CDR1:5q32-33) often deleted in the 5q- syndrome [2] and 
a proximal region (CDR2:5q31) in higher-risk MDS and 
AML [13]. SNP-array-based karyotyping helped to further 
refine the boundaries of the CDR (CDR1;145,299,747-
153,828,955 and CDR2;137,500,665-139,471,723), and 
commonly retained regions (CRR1;from the centromere 
to 5q14.2 and CRR2;from 5q34 to the telomere) [5]. 
Patients with small interstitial deletions were shown 
to have a better outcome as compared to those with 
larger deletions [5]. Haploinsufficiency of several genes 
in the CDRs likely contributes to specific phenotypic 
features in del(5q). For instance, heterozygous deletions 
resulting in haploinsufficient expression of RPS14 is a 
key determinant of ineffective erythropoiesis [14], while 
thrombocytosis and megakaryocytic dysplasia may be 
related to haploinsufficient miR-145/miR-146a [15]. 
However, experimental knockdown of these genes did 
not result in a growth advantage and haploinsufficiency 
is not uniformly present in all cases to explain clonal 
dominance. Recurrent hemizygous mutations of genes 
within the deleted locus have not been identified with the 
notable exception CSNK1A1 missense mutations found 
in only 3/40 del(5q) cases, but absent in heterozygous 
configuration [16]. Moreover, most of del(5q) cases 
involve large deletions encompassing both CDRs, and 
thus identification of genes contributing to individual 
clinical phenotypes has been challenging. It is likely 
that pathogenetic mechanisms in del(5q) may involve 
hemizygous mutations or haploinsufficiency and be 
modified by additional somatic lesions affecting genes on 
other chromosomes. Furthermore, the position of del(5q) 
within the clonal hierarchy might also affect the phenotype 
and clinical behavior.
To characterize the genetic and genomic complexity 
and clonal hierarchy in myeloid neoplasms with 5q 
abnormalities, we used next generation sequencing (NGS), 
including whole exome sequencing (WES) and targeted 
multiamplicon deep sequencing in a cohort of patients 
with del(5q) in a comparison to patients with diploid 
chr5. In addition, to explore ancestral events in del(5q), 
we compared clonal size of individual somatic mutations 
with that of del(5q) identified by WES.
RESULTS
Detection of mutations within CDRs and CRRs 
in del(5q) 
Using a combination of cytogenetic methods, 
including SNP-array karyotyping, FISH analysis and/
or metaphase cytogenetics, we analyzed 1472 patients 
with myeloid neoplasms and identified various types of 
del(5q) in 178 (12%, isolated del(5q) N = 43, del(5q) with 
additional chromosome abnormality N = 135) patients 
and 5q uniparental disomy (UPD) in 8 (0.5%) (Table 1). 
After we defined large proximal (CRR1 5q11.1 to 5q14.2, 
48400001-81634579) and distal (CRR2 5q34 to 5q35.3, 
164213764-180915260) commonly retained genomic 
segments, as well as a region including the well-known 
CDR (5q31.1-5q33.1) as an interstitial deleted region 
(IDR) (5q14.2 to 5q34, 81634580-164213763), we 
correlated clinical characteristics with the extent of the 
deleted area. Interstitial deletions were frequently seen in 
low-risk MDS, while deletions involving the CRR1 and/
or CRR2 (extended deletions) were more prevalent in 
high-risk MDS (RAEB1,RAEB2) and in AML compared 
to low-risk MDS (RCUD, RCMD, 5q-, MDS-U, RARS) 
(P < .0001, Figure 1A). No del(5q) case was observed 
within the MPN cohort (N = 81).
Our investigations focused on mutational events in 
5q genes in both diploid and 5q deletion cases; 329 non-
del(5q) cases and 60 cases of del(5q), including 13 low-
risk MDS, 8 high-risk MDS, 14 sAML, 4 MDS/MPN(3 
CMML and 1 MDS/MPN-U) and 21 pAML. In addition, 
8 selected genes on chr5 (e.g., DHX29, GPR98, APC, 
CSNK1A1, CSF1R, NPM1, SIMC1 and DDX41), found 
to be mutated in WES cohort studies were investigated 
in other cases (N = 627) by targeted sequencing 
(Supplementary Table S1). We identified 583 non-silent 
alterations on chr5 (6% of whole exome alterations) 
predominantly located on 5q (505 alterations/275 genes). 
After stringent filtering to avoid false positives [18], 
we narrowed the focus of our investigations to “tier 1” 
mutations. All candidate alterations were validated by 
Sanger sequencing and/or targeted deep sequencing of 
approximation of clonal size of del(5q) and clonal burden for somatic mutations. 
Interpretation: Our results illuminate the spectrum of molecular defects characteristic 
of del(5q), their clinical impact and succession of stepwise evolution.
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DNA from both neoplastic and germ line DNA. In the 
entire cohort we identified 257 somatic mutations in 159 
genes through 5q; present in 26% (16/60) of del(5q) cases 
and in 40% (131/327) of 5q diploid cases (Figure 1B–1C), 
including well-known NPM1 mutations (N = 50 
mutations), but also the newly identified recurrently 
mutated genes CSNK1A1, G3BP1 and DDX41 (Figure 2). 
No homozygous mutations were found within the long 
arm of chr5 in UPD cases.
When we focused on mutations in the CDR, we 
found 70 alterations in 57 genes (27% of all alterations 
on 5q) including CSNK1A1 (5q32) and novel recurrently 
Table 1: Analysis cohort and frequency of 5q deletions and loss of heterozygosity
MDS-Low Total 316
(RCUD / RCMD / 5q- / MDS-U / RARS)
del(5q) 49
UPD5q 3
total 5q abnormality 51 (16%)
MDS-High Total 192
(RAEB 1/2) del(5q) 44
UPD5q 2




















total 5q abnormality 186 (13%)
MDS, myelodysplastic syndromes; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia 
with multilineage dysplasia; 5q-, MDS with isolated del(5q); MDS-U, MDS unclassifiable; RARS, refractory anemia with 
ring sideroblasts; RAEB, refractory anemia with excess blasts; MDS/MPN, myelodysplastic/myeloproliferative neoplasms, 
including CMML, JMML, MDS/MPN-U, RARS-T, and atypical CML; MPN, myeloproliferative neoplasms, including MPN, 
idiopathic MF, systemic mastocytosis, essential thrombocythemia, CML, and polycytemia vera ; pAML, primary acute myeloid 
leukemia; sAML, secondary acute myeloid leukemia, includes therapy related myeloid malignancies.
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Figure 1: Whole spectrum of deletion 5q (del(5q)) and somatic mutations on chromosome 5q. (A) Number of various types 
of del(5q) lesions affecting interstitial and commonly retained regions (CRRs) in each disease phenotype. For detection of del(5q), SNP-
array karyotyping and metaphase cytogenetics were applied (N = 1476). interstitial deletion: deletions within 5q14.2 to 5q34, extended 
deletion: deletions involving the CRR1 and/or CRR2, Low-risk MDS includes: refractory cytopenia with unilineage dysplasia, refractory 
cytopenia with multilineage dysplasia, MDS with isolated del(5q), MDS unclassifiable, and refractory anemia with ring sideroblasts. High-
risk MDS includes refractory anemia with excess blasts. *P < .001. (B) Frequency of cases with mutations (mt) on chromosome 5 (chr5) 
in each copy-number status (diploid or deletion) as demonstrated by pie chart. *In a case with del(5q), a heterozygous mutation of a gene 
located on the non-deleted region of chr5 was identified.  Venn diagram showing the number of mutated genes categorized by their zygosity 
(heterozygous, hemizygous, hemizygous and heterozygous). (C) Mutations on chr5 detected by whole-exome sequencing (N = 389) were 
shown in red dots (see Supplementary Table S3 for individual genes). Copy number status of chr5 was demonstrated as follows: diploid 5q, 
green and blue lines; and del(5q), a red dashed line. Two commonly retained regions (CRR1 and CRR2) and a commonly deleted region 
(CDR), defined by SNP-A karyotyping analyses, are represented by vertical rectangles.
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mutated genes G3BP1 (N = 2, 5q33.1). Hemizygous 
alterations in most of cases were found in the CDR (N = 
8, Figure 1C, Figure 2). Mutations of CSNK1A1 (3/131 
del(5q); 0/429 diploid cases) and KDM3B (3/60 del(5q); 
0/331 diploid cases) were detected only in cases with 
del(5q). Mutations were found outside of the CDR, 
including APC (N = 4), FAM170A (N = 2) and GPR98 
(N = 2), the latter previously found to be involved in 
germ line mutation in Usher syndrome. In serially 
studied specimens a GPR98 mutation appeared initially 
in a heterozygous configuration and was found later to be 
hemizygous upon evolution of del(5q). No mutations in 
CDC25C, CTNNA1, RPS14, PPP2CA and SPARC were 
identified. In genes corresponding to CRR1 we found 
29 heterozygous alterations, including MAP1B. We also 
detected 96 alterations in CRR2, including NPM1 (N = 50), 
SIMC1 (N = 4), DDX41 (N = 10) and FLT4 (N = 1); these 
mutations occurred only in a heterozygous configuration. 
Expression of frequently mutated genes on chr5
Haploinsufficiency caused by deletion of 5q 
involving multiple genes is likely the key pathogenetic 
mechanism in 5q- syndrome. We hypothesized that 
heterozygous hypomorphic mutations ultimately result 
in haploinsufficient expression, thereby phenocopying 
haploinsufficiency due to deletions. We investigated the 
expression levels of genes located on 5q in comparison 
between cases with/without del(5q) focusing on 
genes which have been previously reported or we 
have found affected by heterozygous mutations. For 
definition of haploinsufficiency we set the cut-off 
value < 60% of normal. In total, 12/27 genes showed 
haploinsufficient expression in del(5q), with the majority 
of haploinsufficient genes located in the CDR (7 genes) 
or CRR2 (3 genes) (Figure 2). Within the CDR, G3BP1, 
CD74 and CSNK1A1 exhibited both haploinsufficiency 
Figure 2: Zygosity of mutations and haploinsufficiency of the genes on chr5. An ideogram of chr5 in the left panel demonstrates 
2 commonly retained regions (CRR1 and CRR2), a commonly deleted region (CDR) and the locations of the genes mutated in this study 
or previously reported to be pathologically important. Each somatic mutation was shown according to the configuration of zygosity; 
hemizygous (open diamonds) and heterozygous mutations (solid diamonds). In the right panel, the ratio (%) of the gene expression in each 
case with del(5q) (N = 5–21) was calculated as divided by the mean value in normal diploid chr5q samples (N = 17–162). The ratios in 
individual del(5q) cases were shown by gradient blue and gray plots as indicated in the figure. Decreased expressions less than 60% were 
considered haploinsufficient.
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and somatic mutations, whereas PPP2CA, CTNNA1 and 
CDC25C showed haploinsufficient expression but no 
mutations. SH3RH2 and SH3TC2 genes did not display 
haploinsufficiency, while somatic events of these genes 
were noted. Other recurrently mutated genes located 
outside of the CDR: such as APC, DDX41 and MAML1 
also showed haploinsufficient expression; however, mRNA 
levels of GPR98, FAM170A, a cluster of protocadherin 
family genes and NPM1 were not decreased in deletion 
cases. 
Del(5q) and genetic events on other 
chromosomes
The associated mutational landscape outside of the 
del(5q) region may also affect the clinical and biological 
features of del(5q) cases. We thus analyzed the potential 
relationship of somatic mutations observed in other 
chromosomes in del(5q) cases. Globally, 5q- syndrome 
cases were associated with lower numbers of mutations 
(average 2.5 mutations/case) compared to IDR deletions 
(9.5 mutations) and patients with extreme deletions 
(involving CRR1 and CRR2; on average 18 mutations) 
by WES. TP53 mutations were associated with del(5q) 
as previously described by our group [19] and others 
[20–22]. In contrast, 10/15 of top mutated genes showed 
a significantly mutual exclusivity with del(5q) (e.g., 
TET2, NPM1, FLT3-ITD/TKD) (Figure 3A). Mutations 
of DNMT3A, SF3B1, ZRSR2, NRAS and BCOR were 
evenly distributed. The correlation of TP53 mutations 
with del(5q) was most prominent. TP53 mutations with 
del(5q) was mostly occurred with other chromosome 
abnormality, though, only 1 case was seen with isolated 
del(5q) (Supplementary Table S2). In low risk MDS, TP53 
mutations were detected in 13% of del(5q) cases and in 
only 0.5% of diploid 5q cases (Figure 3B; P = .0001). 
Among high-risk MDS, TP53 was mutated in 42% 
of del(5q) vs. 4% of diploid 5q patients (Figure 3B; 
P < .0001). When we focused on the extent of the deletion, 
somatic TP53 mutations were particularly frequent (39%, 
17/38) in cases whose deletion involved both CRR1 and 
CRR2, and in 32% (12/38) of interstitial deletion cases 
(Figure 3C, P = .03). Moreover, large deletions tended 
to be a part of complex karyotypes and 17p abnormality 
(Figure 3D).
Prognostic impact
To investigate clinical implications, we initially 
assessed the impact of the deleted lesion on clinical 
outcomes, in which follow-up data were available. As 
expected, patients with isolated del(5q) showed better 
prognosis compared with del(5q) with other chromosomal 
abnormality (P < .001, Figure 4A). When we investigated 
the size of deletion, patients with both CRR1/CRR2 lesions 
(involving the 5q extremes) showed a worse prognosis 
compared with cases including CRR1 or CRR2, or with 
IDR lesions (P = .01, Figure 4A). We also investigated 
the impact of the presence of TP53 mutations (TP53MT) 
as the most common mutational event associated with 
del(5q). Predictably, survival among patients with del(5q) 
was inferior for TP53MT compared to wild type TP53 
(TP53WT) cases (P < .001, Figure 4A). Furthermore, 
there were significant survival differences reflective of the 
previously described differences in the extent of deleted 
regions on 5q in TP53WT cases (P < .001, Figure 4B). 
TP53MT cases showed inferior outcome regardless of 
deleted region (Figure 4B).
When we focused on the prognostic value of low-
expressed genes in primary AML cohort,  low expression 
of G3BP1 and DDX41 correlated with a shorter survival 
(P < .001 and P = .04, Figure 4C), an effect that was not 
seen in CSNK1A1 cases (Figure 4C). We also could not 
find association between low-expression and outcome in 
MAP1B, GPR98 and FAM170A which did not reach the 
haploinsufficiency cut off in our cohort (data not shown). 
Del(5q) and hierarchical clonal architecture
It has been presumed that the del(5q) is the ancestral 
event in the myeloid neoplasms harboring this lesion [23]. 
Using deep sequencing and ’allelic imbalance’ we can 
determine the position of del(5q) in the hierarchical clonal 
architecture [24]. In our cohort, del(5q) was present in 
17–98% of tumor cells and there was good correlation to 
the size of del(5q) clone by FISH (r = .94; Figure 5A). We 
identified three patterns of recurrent clonal architecture in 
del(5q) cases (Figure 5B) i) apparent pathogenic somatic 
mutations precede the deletion event (31%), ii) del(5q) 
appears to precede any other somatic mutation (19%) 
and iii) the succession cannot be determined because of 
expanded clones with similar size (“clonal saturation”) 
i.e., these cases were not informative. In our cohort, 
among the majority of cases in which del(5q) was a 
secondary lesion, in 64% of instances a TP53 mutation 
was the ancestral event and in 27% of cases the primordial 
lesion was DNMT3A mutation (Figure 5C). When we 
compared different time points in same case (MDS-phase 
and leukemic phase), the proportion of cells affected by 
TP53 mutation was more prominent than that of del(5q) 
(92% vs. 17%, Figure 5C right). In contrast, CSNK1A1 
mutation occurred in the remaining allele after del(5q) 
(Figure 5D). We also detected 1 case in which del(5q) 
was asserted to be ancestral, and the TP53 mutation was 
detected as a secondary event. 
DISCUSSION
Our study identified a cohort of 178 patients with 
various forms of del(5q) to answer several fundamental 
questions related to the pathogenesis of myeloid 
malignancies associated with these deletions: i) is del(5q) 
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Figure 3: Presence of coexisting genetic events with del(5q). (A) In total, 1020 cases were analyzed for mutational landscape 
using NGS. Among them, 369 cases were MDS, 148 cases were MDS/MPN, 56 cases MPN, 146 cases were secondary-AML and 301 
cases were primary-AML. Number of mutations were compared between cases with and without del(5q) (N = 894 and 126, respectively) 
*P < .005, **P < .0001. (B) Frequencies of TP53 mutations were compared between del(5q) and diploid chr5q cohorts (Low-risk MDS; 
RCUD, RCMD, 5q-synd, MDS-U and RARS, High-risk MDS; RAEB-I and RAEB-II), *P < .001. (C) Frequencies of TP53 mutations 
coexisting with subsets of del(5q) (as below) were individually compared to that with whole del(5q). IDR, interstitial deleted region 
(affecting q14.2-q34); CRR1, commonly retained region 1 (q11.1-q14.2); CRR2, commonly retained region 2 (q34-qter); CRR1/CRR2, 
deleted region spanning from CRR1 to CRR2, *P < .001. (D) Mutational spectrum associated with subsets of del(5q) were demonstrated 
according to the functionally relevant grouping of genes frequently mutated in myeloid neoplasms. Positive genes in each pathway were as 
follows: spliceosome, SF3B1, LUC7L2 and PRPF8; KDM family, KDM3B and KDM6B; Ras family, KRAS, NRAS and RIT1.
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associated with recurrent hemizygous mutations; ii) may 
heterozygous mutations corresponding to haploinsufficient 
genes mimic the phenotype of the deletion; iii) are gene 
mutations on other chromosomes recurrent in del(5q); 
iv) what is the architecture and clonal evolution pattern 
in del(5q) myeloid neoplasms? Does 5q still stand as the 
primordial lesion in the light of data generated from the 
use of the new genomic platforms? 
We found several somatic hemizygous mutations in 
del(5q) cases, including G3BP1 and CSNK1A1. Mutations 
in CSNK1A1 were found in a canonical E98 position as 
recently reported [16, 25]; only hemizygous mutations 
were found with del(5q) in the context of various 
clinical subtypes, including aggressive diseases RAEB-1 
or therapy-related MDS. CSNK1A1 E98 mutations 
increase β-catenin activity thereby providing selective 
growth advantage. G3BP1 is another gene encoded 
within the CDR, and unlike CSNK1A1 mutations those in 
G3BP1 occurred both in heterozygous and hemizygous 
configuration. G3BP1 is known to control p53 activity 
through a dual pathway involving direct protein interaction 
of G3BP1-p53 and deubiquitination by regulating the 
ubiquitine specific peptidase USP10 [26]. 
Several other hematopoiesis-related genes and 
tumor suppressor genes are located in the CDR (e.g., 
CTNNA1, PPP2CA, EGR1, SPARC, RPS14 and CDC25C) 
with previously reported [14, 27–31], however, we were 
unable to detect hemi- or heterozygous mutations in 
Figure 4: Survival analysis in the cases with del(5q). (A) (Left panel) Overall survival (OS) for patients with isolated del(5q) was 
compared among the del(5q) with other abnormality(del(5q) with abn). (Middle panel) Overall survival (OS) for patients with del(5q) was 
compared among the subgroups of 3 deleted regions as mentioned in Figure 1C. (Right panel) OS for patients with del(5q) were compared 
according to the TP53 mutational status. TP53MT, TP53 mutation; TP53WT, TP53 wild type. (B) OS was compared in 3 groups of each 
deleted region as above in the cohorts of TP53WT (left) and TP53MT (right). (C) OS was compared between low (under mean-1.5 S.D. in 
all cohort) and normal-range expression of 3 genes in each panel (CSNK1A1, G3BP1 and DDX41).
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these genes. It is possible that they contribute to clinical 
heterogeneity, shape the clinical phenotype or modulate 
the growth advantage of the del(5q). For the purpose of 
our investigations we hypothesized that haploinsufficient 
genes in del(5q) may also be affected by loss of function/
hypomorphic mutations in diploid cases, and we have 
identified several genes fitting this profile. They were 
affected only in a minority of patients, and most did not 
recapitulate the clinical features of del(5q). Of note is that 
even the haploinsufficient expression showed variability 
Figure 5: Ancestral mutations and subsequent del(5q) clones. (A) Correlation between FISH and deep sequencing on the 
detection of del(5q) clone. (B) Initial genetic events (mutations or del(5q)) were determined by the size of affected clonal cell populations 
based on the following assessments (bar graph). Variant allelic frequencies (VAF) of somatic mutations were adjusted by copy numbers 
and LOH was based on SNP-A results. Pathogenic genes mutated as initial events included TP53, DNMT3A, NCOR2 and PRPF8 as shown 
in Figure 5C. VAF of SNPs with a deleted-allele due to del(5q) were calculated for allelic imbalance as mentioned in the methods section. 
Inconclusive cases without discrimination were categorized as clonal saturation. Distribution of the disease phenotypes in each clonal 
pattern was demonstrated by colors as indicated. (C) Clonal architecture of the cases (N = 9) with initial driver mutations prior to del(5q) 
was demonstrated by overlaid double-oval figures (left) and a serial-assessment figure (right). Percentages indicate the fraction of the cells 
affected by mutations or del(5q). (D) In 3 other cases, del(5q) was shown to be a primary event.
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among del(5q) cases: while average expression values 
may be decreased in del(5q) cohorts, specific expression 
is indeed haploinsufficient only in a portion of cases, 
and may in part reflect the relative percentage of the 
malignant clone in each patient. These differences in the 
degree of haploinsufficiency may explain, in addition 
to the size of deleted region, the intrinsic diversity of 
del(5q). Epigenetic regulation also affects the expression 
of each genes on del(5q) whereby deletion of unsilenced 
allele could even lead to gain of silencing. However, 
there would be no impact if silenced allele is deleted 
and thus may not be a key determining factor for the 
degree of haploinsufficiency. Because del(5q) occurred 
in one allele but epigenetic regulation (hyper- or hypo 
methylation) occurred in both allele, most likely at 
random. Nevertheless, several genes were found to be 
haploinsufficient and affected by somatic mutations, 
including HDAC3, CSNK1A1, G3BP1 and DDX41. 
Moreover, the functional role of 5q genes in hematopoiesis 
has been shown using a murine model. 
The number of somatic mutations on other 
chromosomes increased with the increasing length of 
the 5q deletion. Co-occurrence of a TP53 mutation was 
particularly prominent in this del(5q) cohort, as reported 
in other studies [19, 21, 22]. It is still unclear why TP53 
mutations selectively coincide with del(5q), one could 
speculate that loss of p53 function might overcome p53 
tumor suppressor effects and foster leukemia evolution. 
Of note is that there are several gene clusters of negative 
regulators of TP53 on chr5q, such as, PPP2CA, RPS14, 
CSNK1A1 and G3BP1.
Among del(5q) patients we found that inferior 
survival was associated with patients with both deletion 
of CRR1 and CRR2. This relationship became evident 
in the TP53-wild type cohort, whereas there was no 
survival difference in existence of TP53 mutation. The 
larger deletions were frequently associated with other 
chromosomal abnormalities, which associated with 
inferior survival [32, 33]. However, the reasons are still 
unclear. One possibility is that there are several tumor 
suppressor genes in this location and long deletion causes 
multifunctional loss of these genes. Alternatively, other 
gene mutations or loss of function of tumor suppressor 
gene may result in different clinical phenotype of extended 
version of del(5q). We also analyzed impact of a cohort 
of individual genes with low expression, which indicated 
recurrent somatic mutations. Low expression of G3BP1 or 
DDX41 correlated with inferior survival but there was no 
prognostic impact in CSNK1A1, CDC25C and EGR1 (data 
not shown). These results indicate that the presence of low 
expression did not always correlate with survival, and the 
loss of tumorsupressive function may affect their outcome. 
Thus, a loss of tumor suppressive function of G3BP1 or 
DDX41 may lead to leukemic evolution in del(5q). 
To define the position of del(5q) within the clonal 
hierarchy, we have compared the clonal size of somatic 
mutations with that of del(5q) using a novel approach 
focusing on allelic imbalance. While it has been reported 
that del(5q) occurs in stem cells as an ancestral event in 
patients with the 5q- syndrome [23], our results indicate 
that the mutation of TP53 or other driver gene mutations 
such as DNMT3A occurred as initial events followed 
by deletion of 5q in a majority of case. Previously, co-
occurrence of a TP53 mutation was described in various 
del(5q) cohorts [19, 21, 22], but the position of del(5q) 
and TP53 mutation within subclonal hierarchy could not 
be precisely established using Sanger sequencing. In this 
report we were able to overcome this shortcoming using 
NGS. We also found somatic mutation of APC (5q22) as 
initial event in del(5q) case, a role for low expression of 
APC in the pathogenesis of myeloid neoplasms [34].
In summary, comprehensive molecular analyses 
using SNP-A karyotyping, WES and targeted sequencing 
revealed recurrent somatic mutations involving CSNK1A1 
and G3BP1 in the CDR and DDX41 in the CRR in 
myeloid neoplasms with the del(5q). These genes showed 
haploinsufficiency in deleted cases and low expression of 
G3BP1 or DDX41 is associated with poor survival, which 
may be due to loss of function. In addition, in assessing 
allelic imbalance in del(5q), our results suggested that 
del(5q) is not an universal ancestral event. Mutation of 
TP53 is the most common mutation in del(5q) cases and 
may serve as an ancestral event. These data illuminate the 
impact of the del(5q) in myeloid malignancy, providing 
deep insights into the identity and role of key genes.
MATERIALS AND METHODS 
Samples
Paired bone marrow and germ line (GL, CD3+ 
lymphocytes) DNA was obtained from 389 patients with 
various myeloid neoplasms and additional 631 DNA 
samples were included for further targeted resequencing, 
including a total of 178 cases of -5/del(5q) (Table 1). All 
samples were obtained following written informed consent 
approved by the institutional review boards at Cleveland 
Clinic and the University of Tokyo. The Cancer Genome 
Atlas (TCGA) AML data set was obtained from http://
cancergenome.nih.gov/. 
Sequencing, SNP array analysis and gene 
expression 
Single-nucleotide polymorphisms (SNP) array 
analysis and WES was performed by HiSeq 2000 (Illumina) 
and result analyzed as previously described [5]. All the 
selected observations were validated by targeted Sanger 
sequencing or PCR-amplified deep sequencing using 
MySeq (Illumina). Targeted sequencing was performed by 
TruSeq custom amplicon (Illumina). Previously published 
microarray expression data were obtained on a cohort of 
183 MDS patients (-5/del(5q), N = 41) and healthy controls 
(N = 17) (Supplementary Figure S1) [5, 17]. 
Oncotarget6493www.impactjournals.com/oncotarget
Determination of clonal burden
The detection of clonal size of del(5q) was 
accomplished by calculation of allelic imbalance for 
informative SNPs present within deleted region in 
heterozygous configuration in GL. For all heterozygous 
SNPs in the region, label the lost allele A and the retained 
allele B. For reads covering a heterozygous site in the 
sample, the probability that the read will carry the B allele 
is: P[reading B allele] = P[reading B allele | read from 
5q−] × P[read from 5q−]+P[reading B allele/read from non-
5q−] × P[read from non-5q−]. The terms in this expression 
depend on clonal abundance c of the deletion, and may 
be computed as: P[reading B allele/read from 5q−] = 1, 
P[reading B allele/read from non-5q] = 0.5, P[read from 
5q−] = c/(2 × (1–c)+c)=c/(2–c), P[read from non- 5q−] 
= 2 × (1–c)/(2 × (1–c)+c)=(2–2c)/(2–c). Substituting these 
values into the expression and algebraically simplifying 
gives the expected proportion of reads harboring the B 
allele as p = 1/(2–c). Solving for c, the proportion for 
cells harboring the deletion is approximately c≈2–(1/p). 
To combine information from all n (GL) heterozygous 
SNPs in the region, we estimated p across these SNPs as 
1
1
number of reads with allele B










, where the allele Bi for
each SNPi is that with the highest read frequency. 
Statistical analysis
Comparisons of proportions and ranks of variables 
between groups were performed by the χ2 test, Fisher exact 
test, Student t test or Mann-Whitney U test, as appropriate. 
We used the Kaplan-Meier and the Cox method to analyze 
overall survival (OS) with a 2-sided P less than or equal to 
.05 determining significance. 
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